EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease

Manuel Soto-Catalán, Lucas Opazo-Ríos iD, Hernán Quiceno, Iolanda Lázaro, Juan Antonio Moreno iD, Carmen Gómez-Guerrero iD, Jesús Egido, Sebastian Mas-Fontao iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25052961 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Manuel Soto-Catalán und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Spanish Biomedical Universidad Autónoma de Madrid, 28049 Madrid, Spain. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Fatty Liver, Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, MICINN-FEDER, JAM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a prevalent clinical condition associated with elevated morbidity and mortality rates. Patients with MASLD treated with semaglutide, a glucagon-like peptide-1 receptor agonist, demonstrate improvement in terms of liver damage. However, the mechanisms underlaying this beneficial effect are not yet fully elucidated. We investigated the efficacy of semaglutide in halting MASLD progression using a genetic mouse model of diabesity. Leptin-receptor-deficient mice with obesity and diabetes (BKS db/db) were either untreated or administered with semaglutide for 11 weeks. Changes in food and water intake, body weight and glycemia were monitored throughout the study. Body fat composition was assessed by dual-energy X-ray absorptiometry. Upon sacrifice, serum biochemical parameters, liver morphology, lipidomic profile and liver-lipid-related pathways were evaluated. The semaglutide-treated mice exhibited lower levels of glycemia, body weight, serum markers of liver dysfunction and total and percentage of fat mass compared to untreated db/db mice without a significant reduction in food intake. Histologically, semaglutide reduced hepatic steatosis, hepatocellular ballooning and intrahepatic triglycerides. Furthermore, the treatment ameliorated the hepatic expression of de novo lipogenesis markers and modified lipid composition by increasing the amount of polyunsaturated fatty acids. The administration of semaglutide to leptin-receptor-deficient, hyperphagic and diabetic mice resulted in the amelioration of MASLD, likely independently of daily caloric intake, suggesting a direct effect of semaglutide on the liver through modulation of the lipid profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, ExperimentalFatty LiverDiabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like PeptidesHumansAnimalsMiceLipogenesisLeptinObesityLiverBody WeightTriglyceridesMice, ObeseSemaglutide

Stichwörter der Autor:innen

GLP1 receptor agonistsdiabetesinsulin resistanceobesitysemaglutidesteatosis

Substanzen

LeptinTriglyceridesGlucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Spanish Biomedical Universidad Autónoma de Madrid, 28049 Madrid, Spain.
  • Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28029 Madrid, Spain.
  • Facultad de Ciencias de la Salud, Universidad de Las Américas, Concepción-Talcahuano 4301099, Chile.
  • Department of Pathology, Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • Cardiovascular Risk and Nutrition Research Group, Epidemiology and Public Health Program, Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.
  • Department of Cell Biology, Physiology and Immunology, University of Cordoba, 140471 Cordoba, Spain.

ORCID-Profile: Lucas Opazo-Ríos, Juan Antonio Moreno, Carmen Gómez-Guerrero, Sebastian Mas-Fontao

Förderung

  • Instituto de Salud Carlos III
  • MICINN-FEDER
  • JAM
  • Spanish Ministry of Science and Innovation/State Investigation Agency
  • Programa Operativo FEDER Junta de Andalucía
  • Consejería de Salud y Familias-FEDER, Junta de Andalucía
  • Spanish Biomedical Research Centre in diabetes and metabolic diseases (CIBERDEM)
  • Spanish Society of Nephrology (SEN)

Zitieren

APA

Soto-Catalán, M., Opazo-Ríos, L., Quiceno, H., Lázaro, I., Moreno, J. A., Gómez-Guerrero, C., Egido, J., & Mas-Fontao, S. (2024). Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052961

Vancouver

Soto-Catalán M, Opazo-Ríos L, Quiceno H, Lázaro I, Moreno JA, Gómez-Guerrero C, et al. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052961

BibTeX
@article{SotoCataln2024,
  author = {Soto-Catalán, Manuel and Opazo-Ríos, Lucas and Quiceno, Hernán and Lázaro, Iolanda and Moreno, Juan Antonio and Gómez-Guerrero, Carmen and Egido, Jesús and Mas-Fontao, Sebastian},
  title = {Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25052961}
}
Kostenlos starten →